Also trades as: MYX.AX (ASX) · $vol 1M
MAYNF OTC
Mayne Pharma Group Limited
1W: -9.9%
1M: -14.9%
3M: +21.2%
YTD: -3.4%
1Y: -41.2%
3Y: -15.6%
5Y: +676.7%
$2.00
+0.00 (+0.00%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$383M
-6.1% ▼
5Y CAGR: -0.9%
Gross Profit
$192M
-22.4% ▼
5Y CAGR: -0.3%
Operating Income
-$34M
-45.1% ▼
Net Income
$24M
+126.0% ▲
EPS (Diluted)
$0.20
+117.5% ▲
EBITDA
$29M
-30.2% ▼
5Y CAGR: -10.1%
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | $157M | $184M | $388M | $408M | $383M |
| YoY Growth | -60.7% | +16.8% | +111.4% | +5.1% | -6.1% |
| Cost of Revenue | $254M | $157M | $170M | $161M | $191M |
| Gross Profit | $170M | $27M | $219M | $247M | $192M |
| Gross Margin | 108.3% | 14.6% | 56.3% | 60.6% | 50.1% |
| R&D Expenses | $25M | $16M | $22M | $19M | $21M |
| SG&A Expenses | $182M | $184M | $186M | $251M | $205M |
| Operating Expenses | $207M | $213M | $358M | $271M | $226M |
| Operating Income | -$136M | -$186M | -$139M | -$24M | -$34M |
| Operating Margin | -86.3% | -101.6% | -35.8% | -5.8% | -8.9% |
| Interest Expense | $32M | $10M | $35M | $35M | $5M |
| Income Before Tax | -$146M | -$270M | -$190M | -$83M | $36M |
| Tax Expense | $75M | $48M | -$21M | $7M | $5M |
| Net Income | -$209M | $117M | -$174M | -$94M | $24M |
| Net Margin | -133.3% | 63.9% | -44.9% | -23.0% | 6.4% |
| EPS (Diluted) | $-3.20 | $-3.67 | $-2.12 | $-1.14 | $0.20 |
| EBITDA | -$46M | -$174M | -$87M | $42M | $29M |
| Shares Outstanding | 82M | 86M | 80M | 79M | 106M |